Holen Sie sich die Stockscreener-App
0.1743
0.85%
-0.0015
Handel nachbörslich:
.17
-0.0043
-2.47%
Schlusskurs vom Vortag:
$0.1758
Offen:
$0.1801
24-Stunden-Volumen:
570.37K
Relative Volume:
0.07
Marktkapitalisierung:
$4.68M
Einnahmen:
$9.94M
Nettoeinkommen (Verlust:
$-144.49M
KGV:
-0.0345
EPS:
-5.05
Netto-Cashflow:
$-103.90M
1W Leistung:
-5.78%
1M Leistung:
-16.60%
6M Leistung:
-89.81%
1J Leistung:
-97.52%
1-Tages-Spanne:
$0.168
$0.1801
1-Wochen-Bereich:
$0.168
$0.1998
52-Wochen-Spanne:
$0.16
$7.96
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Firmenname
Syros Pharmaceuticals Inc
Sektor
Branche
Telefon
617-744-1340
Adresse
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Vergleichen Sie SYRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.1743 | 4.68M | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-08 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2019-02-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-11-05 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-03-13 | Bestätigt | Wedbush | Outperform |
| 2017-10-31 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-23 | Eingeleitet | ROTH Capital | Neutral |
| 2017-08-10 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
Alle ansehen
Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten
What Did We Find About Insider Trading At Syros Pharmaceuticals Inc (NASDAQ: SYRS)? - Stocks Register
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.17, Down -3.99 - The Dwinnex
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Now Carries A 12-Month Price Target Of $5. - Marketing Sentinel
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Syros Pharmaceuticals Inc [NASDAQ: SYRS] Sees Increase in Stock Value - Knox Daily
Check Out Syros Pharmaceuticals Inc (SYRS)’s Trade Data Rather Than the Analysts’ Views - SETE News
Syros Pharmaceuticals Inc (SYRS) Stock Price and Analyst Predictions - The News Heater
H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral - Knox Daily
Ratio Examination: Syros Pharmaceuticals Inc (SYRS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Fell -2280.95%, Predicting What To Expect In The Near Future - Marketing Sentinel
SYRS News Today | Why did Syros Pharmaceuticals stock go down today? - MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World
Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register
Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com
Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com
SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Finanzdaten der Syros Pharmaceuticals Inc-Aktie (SYRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):